^
    Back
    Association details:
    Biomarker:EGFR L858R + EGFR A871G
    Cancer:Lung Adenocarcinoma
    Drug:Conmana (icotinib) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Invest New Drugs
    Title:

    Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation.

    Published date:
    04/09/2021
    Excerpt:
    ...we present an EGFR exon21 L858R/A871G mutation patient exerted significant benefit to icotinib...Our case report provides promising EGFR-TKI for clinical treatment with EGFR exon21 L858R/A871G mutation in NSCLC.
    DOI:
    https://doi.org/10.1007/s10637-021-01108-3